Using fisetin to improve blood vessel function in older adults
Clinical Translation of Senolytic Therapy with Fisetin to Improve Vascular Function in Older Adults
This study is testing if a natural compound called fisetin can help improve blood vessel function and reduce stiffness in older adults.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | University of Colorado, Boulder Academic / other |
| Drugs / interventions | Dasatinib |
| Locations | 1 site (Boulder, Colorado) |
| Trial ID | NCT06133634 on ClinicalTrials.gov |
What this trial studies
This pilot clinical trial aims to evaluate the effectiveness of intermittent fisetin treatment in enhancing vascular endothelial function and reducing aortic stiffness in older adults. The study will explore the mechanisms by which fisetin may improve vascular health, including its effects on mitochondrial oxidative stress and cellular senescence. Additionally, the trial will assess the safety, tolerability, and adherence to fisetin treatment among participants. By focusing on older adults, the study seeks to address age-related vascular dysfunction.
Who should consider this trial
Good fit: Ideal candidates for this study are older adults aged 65 years or older, particularly postmenopausal women, who are stable in weight and have no serious chronic diseases.
Not a fit: Patients with unstable chronic diseases or those currently taking certain supplements or medications that interact with fisetin may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could lead to improved vascular health and reduced cardiovascular risks in older adults.
How similar studies have performed: While studies in animal models have shown promise for fisetin in improving vascular function, this approach in older adults is novel and has not been previously tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 65 years or older * Women must be postmenopausal * Body mass index (BMI) \<40 kg/m2 * Willing to accept random assignment * Weight stable in the prior 2 months (\<2 kg weight change) and willing to remain weight stable throughout the study * Ability to understand study procedures and to comply with them for the entire length of the study * No blood donation within 8 weeks prior to baseline testing; willingness to abstain from blood donation during the study and for 8 weeks after study completion * Absence of established, serious, unstable, chronic clinical disease (e.g., unstable CVD) as determined by study physician of record based on subject medical history, physical examination, resting ECG and standard clinical blood chemistries Exclusion Criteria: * Inability to refrain from alcohol for 24 hours prior to outcome assessment * Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with established senolytic effects) within 6 months prior to baseline testing; should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the subject by the PI * New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use) * Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use) * Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing * Inability or unwillingness of individual to give written informed consent * Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study * Known hypersensitivity or allergy to fisetin * Blood donation within 2 months prior to baseline testing * Resting blood pressure \>160 mmHg systolic or \>110 mmHg diastolic * Regular vigorous aerobic/endurance exercise
Where this trial is running
Boulder, Colorado
- University of Colorado Boulder — Boulder, Colorado, United States (Recruiting)
Study contacts
- Principal investigator: Matthew J Rossman, PhD — University of Colorado, Boulder
- Study coordinator: Sarah Haydu, MA
- Email: fisetinstudy@colorado.edu
- Phone: 303-735-6410
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.